December 03, 2009
FDA warns of potential cardiovascular risk with Lexiva in HIV-infected patientsThe FDA and GlaxoSmithKline have notified healthcare professionals of a potential association between Lexiva (fosamprenavir calcium) and myocardial infarction and dyslipidemia in HIV-infected adults. The Warnings and Precautions sections of the Lexiva Prescribing Information have been updated to note that increases in cholesterol have occurred with treatment. The labeling now includes a recommendation that triglyceride and cholesterol testing be performed prior to initiating therapy with Lexiva and at periodic intervals during therapy.
Lexiva is indicated for the treatment of HIV-1 infection. Lexiva tablets are available in a 700mg dosage strength, Lexiva Oral Suspension is available in a 50mg/mL dosage strength.
For more information call (888) 825-5249 or visit www.lexiva.com.